SGMT - Sagimet Biosciences Inc.
About Sagimet Biosciences Inc. (https://sagimet.com)
Sagimet Biosciences Inc. is a biopharmaceutical company with drug candidates in clinical trials, specializing in developing therapies that target fatty acid synthase (FASN) inhibition. These treatments are engineered to combat medical conditions stemming from impaired lipid metabolism pathways. Its primary investigational compound, Denifanstat, is a FASN inhibitor currently being evaluated for nonalcoholic steatohepatitis (NASH) and acne. Additionally, Sagimet is advancing TVB-3567, another FASN inhibitor, which targets various forms of cancer. Founded in 2006, the company's main operations are located in San Mateo, California. It was formerly recognized as 3-V Biosciences, Inc. until it rebranded to Sagimet Biosciences Inc. in August 2019.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| David A. Happel | Chief Executive Officer, President & Director | 1962 | $943,883 USD |
| Elizabeth Rozek | Chief Legal & Administrative Officer | 1972 | $669,897 USD |
| Andreas Grauer | Chief Medical Officer | 1961 | $669,064 USD |
| Eduardo Bruno Martins DPhil | Chief Medical Officer | 1963 | $669,064 USD |
| Thierry Chauche | Chief Financial Officer & Principal Accounting Officer | 1976 | $598,045 USD |
| Lucas Pelkmans | Co-Founder | – | – |
| Marie O'Farrell | Chief Scientific Officer | – | – |
| Robert D'Urso | Senior Vice President of New Products | – | – |
| Urs Greber | Co-Founder | – | – |